Phase 2 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)

Trial Profile

Phase 2 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Reltecimod (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Sponsors Atox Bio
  • Most Recent Events

    • 05 Feb 2018 Planned initiation date changed from 1 Apr 2019 to 1 Apr 2018.
    • 05 Dec 2017 New trial record
    • 04 Dec 2017 According to an Atox Bio media release, the company plans to initiate this trial during 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top